SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Aurora Biosciences (ABSC)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Ingenious who wrote (138)7/21/1998 2:18:00 PM
From: Vector1  Read Replies (1) of 359
 
Numerous companies do high throughput screening including virtually every pharma. What makes ABSC interesting is (i) their patent position on the use of florescent technology is very strong, (ii) they are on the verge of developing what they call ultra high throughput screening that has the ability to increase the speed at better than a 10 fold clip. I know of no other independent company which is even close. whether a big pharma has developed such a capability in house is unknown. With the tremendous growth in targets and huge combinatorial libraries high throughput sceening will become increasingly important and I believe pharma will pay for a system that can deliver a 10 fold increase in efficiency.
V1
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News